- Home
- HTOO vs BIAF Comparison
HTOO vs BIAF Comparison
Compare HTOO & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HTOO
- BIAF
- Stock Information
- Founded
- HTOO 2020
- BIAF 2014
- Country
- HTOO Ireland
- BIAF United States
- Employees
- HTOO N/A
- BIAF N/A
- Industry
- HTOO Natural Gas Distribution
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- HTOO Utilities
- BIAF Health Care
- Exchange
- HTOO Nasdaq
- BIAF Nasdaq
- Market Cap
- HTOO 12.3M
- BIAF 14.5M
- IPO Year
- HTOO N/A
- BIAF 2022
- Fundamental
- Price
- HTOO $0.49
- BIAF $1.04
- Analyst Decision
- HTOO Strong Buy
- BIAF Strong Buy
- Analyst Count
- HTOO 1
- BIAF 1
- Target Price
- HTOO $3.50
- BIAF $6.00
- AVG Volume (30 Days)
- HTOO 16.4M
- BIAF 131.4K
- Earning Date
- HTOO 12-24-2024
- BIAF 11-14-2024
- Dividend Yield
- HTOO N/A
- BIAF N/A
- EPS Growth
- HTOO N/A
- BIAF N/A
- EPS
- HTOO N/A
- BIAF N/A
- Revenue
- HTOO $4,580,524.00
- BIAF $9,367,785.00
- Revenue This Year
- HTOO $329.95
- BIAF $285.51
- Revenue Next Year
- HTOO $344.33
- BIAF $20.05
- P/E Ratio
- HTOO N/A
- BIAF N/A
- Revenue Growth
- HTOO N/A
- BIAF 2813.87
- 52 Week Low
- HTOO $0.28
- BIAF $0.83
- 52 Week High
- HTOO $4.65
- BIAF $3.62
- Technical
- Relative Strength Index (RSI)
- HTOO 51.31
- BIAF 42.08
- Support Level
- HTOO $0.42
- BIAF $0.83
- Resistance Level
- HTOO $0.59
- BIAF $1.04
- Average True Range (ATR)
- HTOO 0.11
- BIAF 0.11
- MACD
- HTOO 0.01
- BIAF 0.01
- Stochastic Oscillator
- HTOO 42.65
- BIAF 52.38
About HTOO Fusion Fuel Green PLC
Fusion Fuel Green PLC is a company that has developed a Green Hydrogen production technology. It is focused on generating cost-effective and competitively priced Green Hydrogen.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.